Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -48,259 | -27,520 | -19,029 | -18,054 | -14,786 |
| Depreciation Amortization | 61 | 26 | 177 | 7 | N/A |
| Accounts receivable | N/A | N/A | 40 | 70 | -110 |
| Accounts payable and accrued liabilities | 147 | 272 | -504 | 61 | -631 |
| Other Working Capital | 56 | 205 | 235 | 171 | -1,765 |
| Other Operating Activity | 20,210 | 7,869 | 996 | 394 | 2,995 |
| Operating Cash Flow | $-27,787 | $-19,148 | $-18,085 | $-17,351 | $-14,297 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2,505 | -37,004 | 11,671 | -15,763 | N/A |
| PPE Investments | -13 | N/A | -14 | -243 | N/A |
| Other Investing Activity | -439 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $2,053 | $-37,004 | $11,657 | $-16,006 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -249 | -43 |
| Common Stock Issued | 108,463 | 103,478 | 8,544 | 44 | 41,214 |
| Other Financing Activity | 0 | 0 | -139 | 0 | -78 |
| Financing Cash Flow | $108,463 | $103,478 | $8,405 | $-205 | $41,094 |
| Beginning Cash Position | 56,491 | 9,165 | 7,189 | 40,750 | 13,954 |
| End Cash Position | 139,220 | 56,491 | 9,165 | 7,189 | 40,750 |
| Net Cash Flow | $82,730 | $47,325 | $1,977 | $-33,562 | $26,797 |
| Free Cash Flow | |||||
| Operating Cash Flow | -27,787 | -19,148 | -18,085 | -17,351 | -14,297 |
| Capital Expenditure | -13 | N/A | -14 | -243 | N/A |
| Free Cash Flow | -27,800 | -19,148 | -18,099 | -17,594 | -14,297 |